FibroGen China, a partner of AstraZeneca, has received marketing approval from the China's National Medical Products Administration for Roxadustat intended to treat anaemia in chronic kidney disease patients on dialysis, it was reported yesterday.
The product is a hypoxia-inducible factor prolyl hydroxylase inhibitor indicated to treat patients who use haemodialysis or peritoneal dialysis. It is intended to help induce coordinated erythropoiesis, increase red blood cell count and maintain plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of chronic kidney disease patients.
The approval was based on an open-label and active-control 26-week phase III trial in dialysis dependent- chronic kidney disease patients with anaemia who have been earlier treated with various forms of a generic erythropoiesis-stimulating agent. These patients were randomised to secure either roxadustat or epoetin alfa in the trial. AstraZeneca has collaborated with FibroGen China to develop and commercialise roxadustat in China.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling